Skip to main content
Premium Trial:

Request an Annual Quote

Dicerna Presents Preclinical Data on Primary Hyperoxaluria Type 1 Drug

Premium

NEW YORK (GenomeWeb) – Dicerna Pharmaceuticals this week announced preclinical data showing that its investigational primary hyperoxaluria type 1 (PH1) therapy DCR-PH1 could silence expression of its target by as much as 97 percent in a mouse model of the disease.

PH1 is a rare, inherited autosomal-recessive condition characterized by the liver's inability to metabolize a precursor of oxalate due to disruption of an enzyme called alanine-glyoxylate aminotransferase 1 (AGT1). As a result, calcium oxalate builds up in renal tubules causing kidney stones and fibrosis.

Dicerna's drug is designed to inhibit HAO1, a gene that produces glycolate oxidase, which is an enzyme upstream of AGT1.

In the preclinical studies, which were detailed at the 11th International Primary Hyperoxaluria Workshop, Dicerna and academic collaborators specifically demonstrated that a single dose of DCR-PH1 led to a 97 percent reduction of the HAO1 transcript in the liver and significant reductions in urinary oxalate to near baseline levels.

Dicerna has said it expects to begin Phase I testing of DCR-PH1 in 2015.

The Scan

Genome Sequences Reveal Range Mutations in Induced Pluripotent Stem Cells

Researchers in Nature Genetics detect somatic mutation variation across iPSCs generated from blood or skin fibroblast cell sources, along with selection for BCOR gene mutations.

Researchers Reprogram Plant Roots With Synthetic Genetic Circuit Strategy

Root gene expression was altered with the help of genetic circuits built around a series of synthetic transcriptional regulators in the Nicotiana benthamiana plant in a Science paper.

Infectious Disease Tracking Study Compares Genome Sequencing Approaches

Researchers in BMC Genomics see advantages for capture-based Illumina sequencing and amplicon-based sequencing on the Nanopore instrument, depending on the situation or samples available.

LINE-1 Linked to Premature Aging Conditions

Researchers report in Science Translational Medicine that the accumulation of LINE-1 RNA contributes to premature aging conditions and that symptoms can be improved by targeting them.